Last 12 months
Inside the activity.
0 purchase rows · 64 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 24 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 12 |
| Mar 2026 | 0 | 13 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2026 Filed Feb 25, 2026 22:31 UTC |
Berry Lance AEVP, COO, CFO & Treasurer
|
GrantCommon Stock | 37,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011825 · wk-form4_1772058711.xml · nonDerivative · entry 3 Berry Lance A · CIK 0001478716 · EVP, COO, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,447 F3 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:31 UTC |
Berry Lance AEVP, COO, CFO & Treasurer
|
SaleCommon Stock | 4,485 | $35.69 | $160,083.11 |
DisclosureSEC source: 0001628280-26-011825 · wk-form4_1772058711.xml · nonDerivative · entry 2 Berry Lance A · CIK 0001478716 · EVP, COO, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,965 F2 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:30 UTC |
Davis John EChief Commercial Officer
|
GrantCommon Stock | 20,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011820 · wk-form4_1772058656.xml · nonDerivative · entry 3 Davis John E · CIK 0001653206 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,306 F3 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:30 UTC |
Davis John EChief Commercial Officer
|
SaleCommon Stock | 2,075 | $35.69 | $74,062.98 |
DisclosureSEC source: 0001628280-26-011820 · wk-form4_1772058656.xml · nonDerivative · entry 2 Davis John E · CIK 0001653206 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,868 F2 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:43 UTC |
Horton AmyVP, Chief Accounting Officer
|
SaleCommon Stock | 1,731 | $37.59 | $65,064.83 |
DisclosureSEC source: 0001628280-26-011843 · wk-form4_1772059387.xml · nonDerivative · entry 1 Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,327 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:36 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
SaleCommon Stock | 2,423 | $37.59 | $91,075.72 |
DisclosureSEC source: 0001628280-26-011837 · wk-form4_1772058983.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,180 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:35 UTC |
Holloway Jean FSVP, General Counsel
|
SaleCommon Stock | 3,079 | $37.59 | $115,733.45 |
DisclosureSEC source: 0001628280-26-011833 · wk-form4_1772058946.xml · nonDerivative · entry 1 Holloway Jean F · CIK 0001540065 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,871 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:34 UTC |
Mackin James PPresident & CEO
|
SaleCommon Stock | 20,962 | $37.59 | $787,919.66 |
DisclosureSEC source: 0001628280-26-011831 · wk-form4_1772058879.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 780,031 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:31 UTC |
Berry Lance AEVP, COO, CFO & Treasurer
|
SaleCommon Stock | 4,981 | $37.59 | $187,225.83 |
DisclosureSEC source: 0001628280-26-011825 · wk-form4_1772058711.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · EVP, COO, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,450 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:30 UTC |
Davis John EChief Commercial Officer
|
SaleCommon Stock | 3,773 | $37.59 | $141,819.52 |
DisclosureSEC source: 0001628280-26-011820 · wk-form4_1772058656.xml · nonDerivative · entry 1 Davis John E · CIK 0001653206 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,943 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| December 31, 2025 Filed Jan 28, 2026 20:47 UTC |
Holloway Jean FSVP, General Counsel
|
GrantCommon Stock | 228 | $26.14 | $5,959.46 |
DisclosureSEC source: 0001628280-26-003820 · wk-form5_1769633226.xml · nonDerivative · entry 2 Holloway Jean F · CIK 0001540065 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,950 F1 · price: These shares were acquired pursuant to Artivion Inc.'s Employee Stock Purchase Plan (ESPP). The shares were acquired in transactions exempt pursuant to 16b-3. Read SEC document |
| December 31, 2025 Filed Jan 28, 2026 20:53 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
GrantCommon Stock | 316 | $26.14 | $8,259.61 |
DisclosureSEC source: 0001628280-26-003824 · wk-form5_1769633614.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,603 F1 · price: These shares were acquired pursuant to Artivion Inc.'s Employee Stock Purchase Plan (ESPP). The shares were acquired in transactions exempt pursuant to 16b-3. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 20:47 UTC |
Davis John EChief Commercial Officer
|
SaleCommon Stock | 5,000 | $45.11 | $225,550.00 |
DisclosureSEC source: 0001628280-25-057614 · wk-form4_1766004447.xml · nonDerivative · entry 1 Davis John E · CIK 0001653206 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,842 F1 · price: Reflects the price the shares were sold. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:59 UTC |
Horton AmyVP, Chief Accounting Officer
|
SaleCommon Stock | 4,572 | $44.42 | $203,083.67 |
DisclosureSEC source: 0001628280-25-056146 · wk-form4_1765317540.xml · nonDerivative · entry 1 Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,058 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 01:54 UTC |
Mackin James PPresident & CEO
|
Exercise / conversionStock Options (Right to buy) · Derivative | 30,921 | $0.00 Strike: $29.62 | $0.00 |
DisclosureSEC source: 0001628280-25-055466 · wk-form4_1764899693.xml · derivative · entry 3 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,921 shares Expires 2026-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 01:54 UTC |
Mackin James PPresident & CEO
|
SaleCommon Stock | 30,921 | $45.46 | $1,405,699.58 |
DisclosureSEC source: 0001628280-25-055466 · wk-form4_1764899693.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 800,993 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F2 · price: Reflects weighted average price. Range of prices were between $45.09 to $45.91. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 01:54 UTC |
Mackin James PPresident & CEO
|
Exercise / conversionCommon Stock | 30,921 | $29.62 | $915,880.02 |
DisclosureSEC source: 0001628280-25-055466 · wk-form4_1764899693.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 831,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 2, 2025. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 01:52 UTC |
Holloway Jean FSVP, General Counsel
|
SaleCommon Stock | 5,267 | $45.30 | $238,595.10 |
DisclosureSEC source: 0001628280-25-055463 · wk-form4_1764899560.xml · nonDerivative · entry 2 Holloway Jean F · CIK 0001540065 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,093 F1 · price: Reflects the price the shares were sold. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 01:52 UTC |
Holloway Jean FSVP, General Counsel
|
SaleCommon Stock | 2,048 | $45.30 | $92,774.40 |
DisclosureSEC source: 0001628280-25-055463 · wk-form4_1764899560.xml · nonDerivative · entry 1 Holloway Jean F · CIK 0001540065 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,360 F1 · price: Reflects the price the shares were sold. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 00:27 UTC |
Mackin James PPresident & CEO
|
Exercise / conversionStock Options (Right to buy) · Derivative | 30,921 | $0.00 Strike: $29.62 | $0.00 |
DisclosureSEC source: 0001628280-25-055181 · wk-form4_1764808042.xml · derivative · entry 3 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,921 shares Expires 2026-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 00:27 UTC |
Mackin James PPresident & CEO
|
SaleCommon Stock | 30,921 | $45.56 | $1,408,729.84 |
DisclosureSEC source: 0001628280-25-055181 · wk-form4_1764808042.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 800,993 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F2 · price: Reflects weighted average price. Range of prices were between $45.25 to $46.09. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 00:27 UTC |
Mackin James PPresident & CEO
|
Exercise / conversionCommon Stock | 30,921 | $29.62 | $915,880.02 |
DisclosureSEC source: 0001628280-25-055181 · wk-form4_1764808042.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 831,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 2, 2025. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 22:07 UTC |
Horton AmyVP, Chief Accounting Officer
|
GiftCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-054812 · wk-form4_1764713252.xml · nonDerivative · entry 1 Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,630 F1 · shares: 750 shares were gifted by the reporting person to a charity. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
Exercise / conversionStock Options (Right to buy) · Derivative | 27,075 | $0.00 Strike: $11.03 | $0.00 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · derivative · entry 8 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,075 shares Expires 2029-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
Exercise / conversionStock Options (Right to buy) · Derivative | 20,301 | $0.00 Strike: $18.44 | $0.00 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · derivative · entry 7 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,301 shares Expires 2029-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
SaleCommon Stock | 8,370 | $45.35 | $379,537.65 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 6 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 F4 · price: Reflects weighted average price. Range of prices were between $45.26 to $45.53. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
SaleCommon Stock | 18,705 | $44.91 | $840,041.55 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 5 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,123 F3 · price: Reflects weighted average price. Range of prices were between $44.26 to $45.255. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
Exercise / conversionCommon Stock | 27,075 | $11.03 | $298,637.25 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 4 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
SaleCommon Stock | 5,715 | $45.35 | $259,152.39 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 3 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 F2 · price: Reflects weighted average price. Range of prices were between $45.26 to $45.54. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
SaleCommon Stock | 14,586 | $44.92 | $655,188.53 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,468 F1 · price: Reflects weighted average price. Range of prices were between $44.26 to $45.25. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
Exercise / conversionCommon Stock | 20,301 | $18.44 | $374,350.44 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
Exercise / conversionStock Options (Right to buy) · Derivative | 1,355 | $0.00 Strike: $11.03 | $0.00 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · derivative · entry 7 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,075 Underlying: Common Stock · 1,355 shares Expires 2029-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
Exercise / conversionStock Options (Right to buy) · Derivative | 2,033 | $0.00 Strike: $18.44 | $0.00 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · derivative · entry 6 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,301 Underlying: Common Stock · 2,033 shares Expires 2029-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
SaleCommon Stock | 1,355 | $44.28 | $59,996.69 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · nonDerivative · entry 5 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 F3 · price: Reflects weighted average price. Range of prices were between $44.26 to $44.35. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
Exercise / conversionCommon Stock | 1,355 | $11.03 | $14,945.65 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · nonDerivative · entry 4 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
SaleCommon Stock | 2,033 | $44.32 | $90,092.40 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · nonDerivative · entry 3 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 F2 · price: Reflects weighted average price. Range of prices were between $44.26 to $44.44. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
Exercise / conversionCommon Stock | 2,033 | $18.44 | $37,488.52 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC |
Stanton Marshall S.SVP, Clinical & MD Affair
|
SaleCommon Stock | 11,888 | $44.14 | $524,736.32 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 F1 · price: Reflects weighted average price. Range of prices were between $43.92 to $44.49. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 18:49 UTC |
Hoff Elizabeth ADirector
|
SaleCommon Stock | 4,200 | $45.10 | $189,411.60 |
DisclosureSEC source: 0001628280-25-053134 · wk-form4_1763578189.xml · nonDerivative · entry 1 Hoff Elizabeth A · CIK 0001949762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,189 F1 · price: Reflects weighted average price. Range of prices were between $44.89 to $45.295. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 18:11 UTC |
Holloway Jean FSVP, General Counsel
|
Exercise / conversionStock Options (Right to buy) · Derivative | 6,394 | $0.00 Strike: $29.62 | $0.00 |
DisclosureSEC source: 0001628280-25-052822 · wk-form4_1763489494.xml · derivative · entry 6 Holloway Jean F · CIK 0001540065 · SVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,394 shares Expires 2026-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 18:11 UTC |
Holloway Jean FSVP, General Counsel
|
SaleCommon Stock | 6,394 | $45.17 | $288,816.98 |
DisclosureSEC source: 0001628280-25-052822 · wk-form4_1763489494.xml · nonDerivative · entry 4 Holloway Jean F · CIK 0001540065 · SVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,408 F1 · shares: The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 18:11 UTC |
Holloway Jean FSVP, General Counsel
|
Exercise / conversionCommon Stock | 6,394 | $29.62 | $189,390.28 |
DisclosureSEC source: 0001628280-25-052822 · wk-form4_1763489494.xml · nonDerivative · entry 3 Holloway Jean F · CIK 0001540065 · SVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 18:03 UTC |
Davis John EChief Commercial Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 6,394 | $0.00 Strike: $29.62 | $0.00 |
DisclosureSEC source: 0001628280-25-052820 · wk-form4_1763488988.xml · derivative · entry 6 Davis John E · CIK 0001653206 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,394 shares Expires 2026-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 18:03 UTC |
Davis John EChief Commercial Officer
|
SaleCommon Stock | 6,394 | $45.17 | $288,816.98 |
DisclosureSEC source: 0001628280-25-052820 · wk-form4_1763488988.xml · nonDerivative · entry 4 Davis John E · CIK 0001653206 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,842 F1 · shares: The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 18:03 UTC |
Davis John EChief Commercial Officer
|
Exercise / conversionCommon Stock | 6,394 | $29.62 | $189,390.28 |
DisclosureSEC source: 0001628280-25-052820 · wk-form4_1763488988.xml · nonDerivative · entry 3 Davis John E · CIK 0001653206 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 17:57 UTC |
Horton AmyVP, Chief Accounting Officer
|
SaleCommon Stock | 6,000 | $45.73 | $274,380.00 |
DisclosureSEC source: 0001628280-25-052817 · wk-form4_1763488672.xml · nonDerivative · entry 1 Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,380 F1 · price: Reflects weighted average price. Range of prices were between $45.605 to $45.91. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 18:11 UTC |
Holloway Jean FSVP, General Counsel
|
Exercise / conversionStock Options (Right to buy) · Derivative | 6,393 | $0.00 Strike: $29.62 | $0.00 |
DisclosureSEC source: 0001628280-25-052822 · wk-form4_1763489494.xml · derivative · entry 5 Holloway Jean F · CIK 0001540065 · SVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,393 shares Expires 2026-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 18:11 UTC |
Holloway Jean FSVP, General Counsel
|
SaleCommon Stock | 6,393 | $45.00 | $287,685.00 |
DisclosureSEC source: 0001628280-25-052822 · wk-form4_1763489494.xml · nonDerivative · entry 2 Holloway Jean F · CIK 0001540065 · SVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,408 F1 · shares: The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 18:11 UTC |
Holloway Jean FSVP, General Counsel
|
Exercise / conversionCommon Stock | 6,393 | $29.62 | $189,360.66 |
DisclosureSEC source: 0001628280-25-052822 · wk-form4_1763489494.xml · nonDerivative · entry 1 Holloway Jean F · CIK 0001540065 · SVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 18:03 UTC |
Davis John EChief Commercial Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 6,393 | $0.00 Strike: $29.62 | $0.00 |
DisclosureSEC source: 0001628280-25-052820 · wk-form4_1763488988.xml · derivative · entry 5 Davis John E · CIK 0001653206 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,393 shares Expires 2026-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.